User menu

Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting

Bibliographic reference Dincq, Anne-Sophie ; Lessire, Sarah ; Douxfils, Jonathan ; Dogné, Jean-Michel ; Gourdin, Maximilien ; et. al. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. In: BioMed Research International, Vol. 2014, p. 385014 [1-16] (2014)
Permanent URL http://hdl.handle.net/2078.1/153284
  1. Husted S., De Caterina R., Andreotti F., Arnesen H., Bachmann F., Huber K., Jespersen J., Kristensen S. D., Lip G. Y. H., Morais J., Rasmussen L. H., Siegbahn A., Storey R. F., Weitz J. I., , Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel : , 10.1160/th14-03-0228
  2. Levy Jerrold H., Faraoni David, Spring Jenna L., Douketis James D., Samama Charles M., Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting : , 10.1097/aln.0b013e318289bcba
  3. Helldén Anders, Odar-Cederlöf Ingegerd, Nilsson Göran, Sjöviker Susanne, Söderström Anders, Euler Mia von, Öhlén Gunnar, Bergman Ulf, Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly, 10.1136/bmjopen-2013-002686
  4. Samama Meyer-Michel, Amiral Jean, Guinet Céline, Flem Léna Le, Seghatchian Jerard, Monitoring plasma levels of factor Xa inhibitors: how, why and when?, 10.1586/ehm.13.11
  5. ten Cate H., Monitoring new oral anticoagulants, managing thrombosis, or both? : , 10.1160/th12-03-0130
  6. Baron Todd H., Kamath Patrick S., McBane Robert D., Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures, 10.1056/nejmra1206531
  7. Sié Pierre, Samama Charles M., Godier Anne, Rosencher Nadia, Steib Annick, Llau Juan V., Van der Linden Philippe, Pernod Gilles, Lecompte Thomas, Gouin-Thibault Isabelle, Albaladejo Pierre, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis, 10.1016/j.acvd.2011.09.001
  8. Beyer-Westendorf J., Gelbricht V., Forster K., Ebertz F., Kohler C., Werth S., Kuhlisch E., Stange T., Thieme C., Daschkow K., Weiss N., Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry, 10.1093/eurheartj/eht557
  9. Siegal Deborah M., Crowther Mark A., Acute management of bleeding in patients on novel oral anticoagulants, 10.1093/eurheartj/ehs408
  10. Schulman S., Crowther M. A., How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch, 10.1182/blood-2011-10-378950
  11. Mega Jessica L., Braunwald Eugene, Wiviott Stephen D., Bassand Jean-Pierre, Bhatt Deepak L., Bode Christoph, Burton Paul, Cohen Marc, Cook-Bruns Nancy, Fox Keith A.A., Goto Shinya, Murphy Sabina A., Plotnikov Alexei N., Schneider David, Sun Xiang, Verheugt Freek W.A., Gibson C. Michael, Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, 10.1056/nejmoa1112277
  12. Oral Rivaroxaban for Symptomatic Venous Thromboembolism, 10.1056/nejmoa1007903
  13. Schulman S., Kakkar A. K., Goldhaber S. Z., Schellong S., Eriksson H., Mismetti P., Christiansen A. V., Friedman J., Le Maulf F., Peter N., Kearon C., , Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis, 10.1161/circulationaha.113.004450
  14. Granger Christopher B., Alexander John H., McMurray John J.V., Lopes Renato D., Hylek Elaine M., Hanna Michael, Al-Khalidi Hussein R., Ansell Jack, Atar Dan, Avezum Alvaro, Bahit M. Cecilia, Diaz Rafael, Easton J. Donald, Ezekowitz Justin A., Flaker Greg, Garcia David, Geraldes Margarida, Gersh Bernard J., Golitsyn Sergey, Goto Shinya, Hermosillo Antonio G., Hohnloser Stefan H., Horowitz John, Mohan Puneet, Jansky Petr, Lewis Basil S., Lopez-Sendon Jose Luis, Pais Prem, Parkhomenko Alexander, Verheugt Freek W.A., Zhu Jun, Wallentin Lars, Apixaban versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa1107039
  15. Patel Manesh R., Mahaffey Kenneth W., Garg Jyotsna, Pan Guohua, Singer Daniel E., Hacke Werner, Breithardt Günter, Halperin Jonathan L., Hankey Graeme J., Piccini Jonathan P., Becker Richard C., Nessel Christopher C., Paolini John F., Berkowitz Scott D., Fox Keith A.A., Califf Robert M., , Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, 10.1056/nejmoa1009638
  16. Connolly Stuart J., Ezekowitz Michael D., Yusuf Salim, Eikelboom John, Oldgren Jonas, Parekh Amit, Pogue Janice, Reilly Paul A., Themeles Ellison, Varrone Jeanne, Wang Susan, Alings Marco, Xavier Denis, Zhu Jun, Diaz Rafael, Lewis Basil S., Darius Harald, Diener Hans-Christoph, Joyner Campbell D., Wallentin Lars, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa0905561
  17. Lassen Michael Rud, Gallus Alexander, Raskob Gary E., Pineo Graham, Chen Dalei, Ramirez Luz Margarita, Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, 10.1056/nejmoa1006885
  18. Lassen Michael Rud, Raskob Gary E, Gallus Alexander, Pineo Graham, Chen Dalei, Hornick Philip, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, 10.1016/s0140-6736(09)62125-5
  19. ERIKSSON B. I., DAHL O. E., ROSENCHER N., KURTH A. A., VAN DIJK C. N., FROSTICK S. P., KÄLEBO P., CHRISTIANSEN A. V., HANTEL S., HETTIARACHCHI R., SCHNEE J., BÜLLER H. R., , Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, 10.1111/j.1538-7836.2007.02748.x
  20. Eriksson B. I., Dahl O. E., Huo M. H., Kurth A. A., Hantel S., Hermansson K., Schnee J. M., Friedman R. J., , Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*) : A randomised, double-blind, non-inferiority trial, 10.1160/th10-10-0679
  21. The Journal of Bone and Joint Surgery, 91, 636 (2009)
  22. Eriksson Bengt I, Quinlan Daniel J, Weitz Jeffrey I, Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development : , 10.2165/0003088-200948010-00001
  23. Stangier Joachim, Clemens Andreas, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, 10.1177/1076029609343004
  24. MacCallum Peter K, Mathur Rohini, Hull Sally A, Saja Khalid, Green Laura, Morris Joan K, Ashman Neil, Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study, 10.1136/bmjopen-2013-003343
  25. Cockcroft Donald W., Gault Henry, Prediction of Creatinine Clearance from Serum Creatinine, 10.1159/000180580
  26. Ferrandis R., Castillo J., de Andrés J., Gomar C., Gómez-Luque A., Hidalgo F., Llau J. V., Sierra P., Torres L. M., The perioperative management of new direct oral anticoagulants: a question without answers : , 10.1160/th12-11-0868
  27. Levy Jerrold H., Key Nigel S., Azran Marc S., Novel Oral Anticoagulants : Implications in the Perioperative Setting, 10.1097/aln.0b013e3181ebdb15
  28. Stangier Joachim, Rathgen Karin, Stähle Hildegard, Gansser Dietmar, Roth Willy, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, 10.1111/j.1365-2125.2007.02899.x
  29. Mueck Wolfgang, Stampfuss Jan, Kubitza Dagmar, Becka Michael, Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban, 10.1007/s40262-013-0100-7
  30. D. Douketis James, Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management, 10.2174/138161210793563338
  31. Raghavan N., Frost C. E., Yu Z., He K., Zhang H., Humphreys W. G., Pinto D., Chen S., Bonacorsi S., Wong P. C., Zhang D., Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans, 10.1124/dmd.108.023143
  32. Stangier Joachim, Clemens Andreas, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, 10.1177/1076029609343004
  33. Sarah Lessire, Anne-Sophie Dincq, Jonathan Douxfils, Bérangère Devalet, Jean-Baptiste Nicolas, Anne Spinewine, Anne-Sophie Larock, Jean-Michel Dogné, Maximilien Gourdin, François Mullier, Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants, 10.1155/2014/616405
  34. Pengo V., Crippa L., Falanga A., Finazzi G., Marongiu F., Palareti G., Poli D., Testa S., Tiraferri E., Tosetto A., Tripodi A., Manotti C., Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation : A consensus document of the Italian Federation of Thrombosis Centers (FCSA), 10.1160/th11-05-0358
  35. Healey J. S., Eikelboom J., Douketis J., Wallentin L., Oldgren J., Yang S., Themeles E., Heidbuchel H., Avezum A., Reilly P., Connolly S. J., Yusuf S., Ezekowitz M., , Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, 10.1161/circulationaha.111.090464
  36. Sherwood M. W., Douketis J. D., Patel M. R., Piccini J. P., Hellkamp A. S., Lokhnygina Y., Spyropoulos A. C., Hankey G. J., Singer D. E., Nessel C. C., Mahaffey K. W., Fox K. A. A., Califf R. M., Becker R. C., , Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), 10.1161/circulationaha.113.005754
  37. Spyropoulos Alex C., Bauersachs Rupert M., Omran Heyder, Cohen Marc, Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy, 10.1185/030079906x104858
  38. Wolf P. A., Abbott R. D., Kannel W. B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, 10.1161/01.str.22.8.983
  39. , Camm A. J., Lip G. Y. H., De Caterina R., Savelieva I., Atar D., Hohnloser S. H., Hindricks G., Kirchhof P., Bax J. J., Baumgartner H., Ceconi C., Dean V., Deaton C., Fagard R., Funck-Brentano C., Hasdai D., Hoes A., Kirchhof P., Knuuti J., Kolh P., McDonagh T., Moulin C., Popescu B. A., Reiner Z., Sechtem U., Sirnes P. A., Tendera M., Torbicki A., Vahanian A., Windecker S., Vardas P., Al-Attar N., Alfieri O., Angelini A., Blomstrom-Lundqvist C., Colonna P., De Sutter J., Ernst S., Goette A., Gorenek B., Hatala R., Heidbuchel H., Heldal M., Kristensen S. D., Kolh P., Le Heuzey J.-Y., Mavrakis H., Mont L., Filardi P. P., Ponikowski P., Prendergast B., Rutten F. H., Schotten U., Van Gelder I. C., Verheugt F. W. A., , , 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association, 10.1093/europace/eus305
  40. Lip Gregory Y.H., Nieuwlaat Robby, Pisters Ron, Lane Deirdre A., Crijns Harry J.G.M., Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach, 10.1378/chest.09-1584
  41. Lip G. Y. H., Andreotti F., Fauchier L., Huber K., Hylek E., Knight E., Lane D., Levi M., Marín F., Palareti G., Kirchhof P., Bleeding risk assessment and management in atrial fibrillation patients : Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis, 10.1160/th11-10-0690
  42. Zarraga Ignatius Gerardo E., Kron Jack, Oral Anticoagulation in Elderly Adults with Atrial Fibrillation: Integrating New Options with Old Concepts, 10.1111/jgs.12042
  43. Lopes Renato D., Alexander John H., Al-Khatib Sana M., Ansell Jack, Diaz Raphael, Easton J. Donald, Gersh Bernard J., Granger Christopher B., Hanna Michael, Horowitz John, Hylek Elaine M., McMurray John J.V., Verheugt Freek W.A., Wallentin Lars, Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale, 10.1016/j.ahj.2009.07.035
  44. Lopes Renato D, Al-Khatib Sana M, Wallentin Lars, Yang Hongqiu, Ansell Jack, Bahit M Cecilia, De Caterina Raffaele, Dorian Paul, Easton J Donald, Erol Cetin, Ezekowitz Justin A, Gersh Bernard J, Granger Christopher B, Hohnloser Stefan H, Horowitz John, Hylek Elaine M, McMurray John JV, Mohan Puneet, Vinereanu Dragos, Alexander John H, Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial, 10.1016/s0140-6736(12)60986-6
  45. Kearon Clive, Akl Elie A., Comerota Anthony J., Prandoni Paolo, Bounameaux Henri, Goldhaber Samuel Z., Nelson Michael E., Wells Philip S., Gould Michael K., Dentali Francesco, Crowther Mark, Kahn Susan R., Antithrombotic Therapy for VTE Disease, 10.1378/chest.11-2301
  46. Jong Paulien G., Coppens Michiel, Middeldorp Saskia, Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term, 10.1111/j.1365-2141.2012.09196.x
  47. Gombotz Hans, Knotzer Hans, Preoperative identification of patients with increased risk for perioperative bleeding : , 10.1097/aco.0b013e32835b9a23
  48. Pisters Ron, Lane Deirdre A., Nieuwlaat Robby, de Vos Cees B., Crijns Harry J.G.M., Lip Gregory Y.H., A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation, 10.1378/chest.10-0134
  49. Fang Margaret C., Go Alan S., Chang Yuchiao, Borowsky Leila H., Pomernacki Niela K., Udaltsova Natalia, Singer Daniel E., A New Risk Scheme to Predict Warfarin-Associated Hemorrhage, 10.1016/j.jacc.2011.03.031
  50. Gage Brian F., Yan Yan, Milligan Paul E., Waterman Amy D., Culverhouse Robert, Rich Michael W., Radford Martha J., Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF), 10.1016/j.ahj.2005.04.017
  51. Apostolakis Stavros, Lane Deirdre A., Guo Yutao, Buller Harry, Lip Gregory Y.H., Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation, 10.1016/j.jacc.2012.06.019
  52. Apostolakis Stavros, Lane Deirdre A., Guo Yutao, Buller Harry, Lip Gregory Y.H., Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients, 10.1016/j.jacc.2012.10.010
  53. Nieto José Antonio, Solano Rosario, Trapero Iglesias Natacha, Ruiz-Giménez Nuria, Fernández-Capitán Carmen, Valero Beatriz, Tiberio Gregorio, Bura-Riviere Alessandra, Monreal Manuel, Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism, 10.1016/j.thromres.2013.06.019
  54. Douketis James D., Spyropoulos Alex C., Spencer Frederick A., Mayr Michael, Jaffer Amir K., Eckman Mark H., Dunn Andrew S., Kunz Regina, Perioperative Management of Antithrombotic Therapy, 10.1378/chest.11-2298
  55. Vuylsteke Alain, Pagel Christina, Gerrard Caroline, Reddy Brian, Nashef Samer, Aldam Poppy, Utley Martin, The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding, 10.1016/j.ejcts.2010.10.003
  56. Spyropoulos A. C., Douketis J. D., How I treat anticoagulated patients undergoing an elective procedure or surgery, 10.1182/blood-2012-06-415943
  57. Heidbuchel Hein, Verhamme Peter, Alings Marco, Antz Matthias, Hacke Werner, Oldgren Jonas, Sinnaeve Peter, Camm A. John, Kirchhof Paulus, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, 10.1093/europace/eut083
  58. Liew Aaron, Douketis James, Perioperative management of patients who are receiving a novel oral anticoagulant, 10.1007/s11739-013-0963-5
  59. Douketis James D, Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians, 10.1016/s0049-3848(02)00387-0
  60. Douketis James D., Berger Peter B., Dunn Andrew S., Jaffer Amir K., Spyropoulos Alex C., Becker Richard C., Ansell Jack, The Perioperative Management of Antithrombotic Therapy, 10.1378/chest.08-0675
  61. Fujita Minoru, Shiotani Akiko, Murao Takahisa, Ishii Manabu, Yamanaka Yoshiyuki, Nakato Rui, Matsumoto Hiroshi, Tarumi Ken-ichi, Manabe Noriaki, Kamada Tomoari, Hata Jiro, Haruma Ken, Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics : Endoscopic biopsy and antithrombotics, 10.1111/den.12303
  62. Weitz J. I., Quinlan D. J., Eikelboom J. W., Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran, 10.1161/circulationaha.112.123224
  63. Greenblatt D J, Elimination Half-Life of Drugs: Value and Limitations, 10.1146/annurev.me.36.020185.002225
  64. Graff Jochen, Harder Sebastian, Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment, 10.1007/s40262-013-0034-0
  65. Siegal D., Yudin J., Kaatz S., Douketis J. D., Lim W., Spyropoulos A. C., Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists: Systematic Review and Meta-Analysis of Bleeding and Thromboembolic Rates, 10.1161/circulationaha.112.105221
  66. Feng L., Li Y., Li J., Yu B., Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices : A meta-analysis, 10.1160/th12-07-0498
  67. Omran H., Bauersachs R., Rübenacker S., Goss F., Hammerstingl C., The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation : Results from the national multicentre BNK Online bRiDging REgistRy (BORDER), 10.1160/th11-12-0827
  68. SPYROPOULOS A. C., DOUKETIS J. D., GEROTZIAFAS G., KAATZ S., ORTEL T. L., SCHULMAN S., , Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy : Standardized reporting for periprocedural antithrombotics, 10.1111/j.1538-7836.2012.04630.x
  69. SCHULMAN S., KEARON C., , Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients : Definitions of major bleeding in clinical studies, 10.1111/j.1538-7836.2005.01204.x
  70. Nascimento Thais, Birnie David H., Healey Jeff S., Verma Atul, Joza Jacqueline, Bernier Martin L., Essebag Vidal, Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey, 10.1016/j.cjca.2013.11.027
  71. Patel Jignesh P., Arya Roopen, The current status ofbridginganticoagulation, 10.1111/bjh.12644
  72. Benzon H. T., Avram M. J., Green D., Bonow R. O., New oral anticoagulants and regional anaesthesia, 10.1093/bja/aet401
  73. Llau Juan V, Ferrandis Raquel, New anticoagulants and regional anesthesia : , 10.1097/aco.0b013e32832eb8ab
  74. Gogarten Wiebke, Vandermeulen Erik, Van Aken Hugo, Kozek Sibylle, Llau Juan V, Samama Charles M, Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology : , 10.1097/eja.0b013e32833f6f6f
  75. Horlocker T, Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation), 10.1053/rapm.2003.50046
  76. Lakkireddy Dhanunjaya, Reddy Yeruva Madhu, Di Biase Luigi, Vanga Subba Reddy, Santangeli Pasquale, Swarup Vijay, Pimentel Rhea, Mansour Moussa C., D'Avila Andre, Sanchez Javier E., Burkhardt J. David, Chalhoub Fadi, Mohanty Prasant, Coffey James, Shaik Naushad, Monir George, Reddy Vivek Y., Ruskin Jeremy, Natale Andrea, Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation, 10.1016/j.jacc.2011.12.014
  77. Kim Jin-Seok, She Fei, Jongnarangsin Krit, Chugh Aman, Latchamsetty Rakesh, Ghanbari Hamid, Crawford Thomas, Suwanagool Arisara, Sinno Mohammed, Carrigan Thomas, Kennedy Robert, Saint-Phard Wouter, Yokokawa Miki, Good Eric, Bogun Frank, Pelosi Frank, Morady Fred, Oral Hakan, Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation, 10.1016/j.hrthm.2012.12.011
  78. Yamaji Hirosuke, Murakami Takashi, Hina Kazuyoshi, Higashiya Shunichi, Kawamura Hiroshi, Murakami Masaaki, Kamikawa Shigeshi, Hirohata Satoshi, Kusachi Shozo, Usefulness of Dabigatran Etexilate as Periprocedural Anticoagulation Therapy for Atrial Fibrillation Ablation, 10.1007/s40261-013-0081-1
  79. NIN TAKAMITSU, SAIRAKU AKINORI, YOSHIDA YUKIHIKO, KAMIYA HIROKI, TATEMATSU YASUSHI, NANASATO MAMORU, INDEN YASUYA, HIRAYAMA HARUO, MUROHARA TOYOAKI, A Randomized Controlled Trial of Dabigatran versus Warfarin for Periablation Anticoagulation in Patients Undergoing Ablation of Atrial Fibrillation : DABIGATRAN VERSUS WARFARIN FOR PERIABLATION ANTICOAGULATION, 10.1111/pace.12036
  80. WINKLE ROGER A., MEAD R. HARDWIN, ENGEL GREGORY, KONG MELISSA H., PATRAWALA ROB A., The Use of Dabigatran Immediately After Atrial Fibrillation Ablation, 10.1111/j.1540-8167.2011.02175.x
  81. Pernod Gilles, Albaladejo Pierre, Godier Anne, Samama Charles M., Susen Sophie, Gruel Yves, Blais Normand, Fontana Pierre, Cohen Ariel, Llau Juan V., Rosencher Nadia, Schved Jean-François, de Maistre Emmanuel, Samama Meyer M., Mismetti Patrick, Sié Pierre, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013, 10.1016/j.acvd.2013.04.009
  82. van Ryn J., Stangier J., Haertter S., Liesenfeld K.-H., Wienen W., Feuring M., Clemens A., Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity : , 10.1160/th09-11-0758
  83. Warkentin T. E., Margetts P., Connolly S. J., Lamy A., Ricci C., Eikelboom J. W., Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding, 10.1182/blood-2011-11-393587
  84. Wanek Matthew R, Horn Edward T, Elapavaluru Subbarao, Baroody Samuel C, Sokos George, Safe Use of Hemodialysis for Dabigatran Removal before Cardiac Surgery, 10.1345/aph.1r081
  85. Khadzhynov D., Wagner F., Formella S., Wiegert E., Moschetti V., Slowinski T., Neumayer H.-H., Liesenfeld K.-H., Lehr T., Härtter S., Friedman J., Peters H., Clemens A., Effective elimination of dabigatran by haemodialysis : A phase I single-centre study in patients with end-stage renal disease, 10.1160/th12-08-0573
  86. Kozek-Langenecker Sibylle A., Perioperative Management Issues of Direct Oral Anticoagulants, 10.1053/j.seminhematol.2014.02.001
  87. Majeed A., Hwang H.-G., Connolly S. J., Eikelboom J. W., Ezekowitz M. D., Wallentin L., Brueckmann M., Fraessdorf M., Yusuf S., Schulman S., Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin, 10.1161/circulationaha.113.002332
  88. Lu Genmin, DeGuzman Francis R, Hollenbach Stanley J, Karbarz Mark J, Abe Keith, Lee Gail, Luan Peng, Hutchaleelaha Athiwat, Inagaki Mayuko, Conley Pamela B, Phillips David R, Sinha Uma, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, 10.1038/nm.3102
  89. Grottke Oliver, van Ryn Joanne, Spronk Henri MH, Rossaint Rolf, Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model, 10.1186/cc13717
  90. Majeed Ammar, Schulman Sam, Bleeding and antidotes in new oral anticoagulants, 10.1016/j.beha.2013.07.001
  91. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
  92. Gallego P., Apostolakis S., Lip G. Y. H., Bridging Evidence-Based Practice and Practice-Based Evidence in Periprocedural Anticoagulation, 10.1161/circulationaha.112.135681
  93. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J.-M., Impact of dabigatran on a large panel of routine or specific coagulation assays : Laboratory recommendations for monitoring of dabigatran etexilate, 10.1160/th11-11-0804
  94. Antovic Jovan P., Skeppholm Mika, Eintrei Jaak, Boija Elisabet Eriksson, Söderblom Lisbeth, Norberg Eva-Marie, Onelöv Liselotte, Rönquist-Nii Yuko, Pohanka Anton, Beck Olof, Hjemdahl Paul, Malmström Rickard E., Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, 10.1007/s00228-013-1550-4
  95. Hawes E. M., Deal A. M., Funk-Adcock D., Gosselin R., Jeanneret C., Cook A. M., Taylor J. M., Whinna H. C., Winkler A. M., Moll S., Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, 10.1111/jth.12308
  96. Douxfils J., Dogné J.-M., Mullier F., Chatelain B., Rönquist-Nii Y., Malmström R. E., Hjemdahl P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate : , 10.1160/th13-03-0202
  97. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogné J.-M., Mullier F., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban : , 10.1160/th13-04-0274
  98. Douxfils J., Chatelain C., Chatelain B., Dogné J.-M., Mullier F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide : , 10.1160/th12-12-0898
  99. Frost Charles, Wang Jessie, Nepal Sunil, Schuster Alan, Barrett Yu Chen, Mosqueda-Garcia Rogelio, Reeves Richard A., LaCreta Frank, Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects : Apixaban single dose safety, PK PD and food effect, 10.1111/j.1365-2125.2012.04369.x
  100. Thrombosis and Haemostasis, 111, 240 (2014)
  101. Francart S. J., Hawes E. M., Deal A. M., Adcock D. M., Gosselin R., Jeanneret C., Friedman K. D., Moll S., Performance of coagulation tests in patients on therapeutic doses of rivaroxaban : A cross-sectional pharmacodynamic study based on peak and trough plasma levels, 10.1160/th13-10-0871
  102. Revue Médicale Suisse, 10, 326 (2014)
  103. Saad Eduardo B., Costa Ieda P., Costa Rodrigo E. da, Inácio Jr Luiz Antônio O., Slater Charles, Camiletti Angelina, Moura Neto Dario G. de, Maldonado Paulo, Camanho Luiz Eduardo, Polanczyk Carisi A., Segurança da ablação de fibrilação atrial com RNI terapêutico: comparação com a transição com heparina de baixo peso, 10.1590/s0066-782x2011005000088
  104. Cappato R., Calkins H., Chen S.-A., Davies W., Iesaka Y., Kalman J., Kim Y.-H., Klein G., Natale A., Packer D., Skanes A., Ambrogi F., Biganzoli E., Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation, 10.1161/circep.109.859116
  105. Cappato R., Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation, 10.1161/01.cir.0000157153.30978.67
  106. Calkins Hugh, Kuck Karl Heinz, Cappato Riccardo, Brugada Josep, Camm A. John, Chen Shih-Ann, Crijns Harry J. G., Damiano Ralph J., Davies D. Wyn, DiMarco John, Edgerton James, Ellenbogen Kenneth, Ezekowitz Michael D., Haines David E., Haissaguerre Michel, Hindricks Gerhard, Iesaka Yoshito, Jackman Warren, Jalife Jose, Jais Pierre, Kalman Jonathan, Keane David, Kim Young-Hoon, Kirchhof Paulus, Klein George, Kottkamp Hans, Kumagai Koichiro, Lindsay Bruce D., Mansour Moussa, Marchlinski Francis E., McCarthy Patrick M., Mont J. Lluis, Morady Fred, Nademanee Koonlawee, Nakagawa Hiroshi, Natale Andrea, Nattel Stanley, Packer Douglas L., Pappone Carlo, Prystowsky Eric, Raviele Antonio, Reddy Vivek, Ruskin Jeremy N., Shemin Richard J., Tsao Hsuan-Ming, Wilber David, 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design, 10.1007/s10840-012-9672-7
  107. Anesthesia and Analgesia, 69, 142 (1989)
  108. Jude B, Lasne D, Mouton C, de Moerloose P, Surveillance de l'anticoagulation des circulations extracorporelles par l'héparine non fractionnée : quels sont les problèmes non résolus ?, 10.1016/j.annfar.2004.02.047
  109. Hussein H. M., Georgiadis A. L., Qureshi A. I., Point-of-Care Testing for Anticoagulation Monitoring in Neuroendovascular Procedures, 10.3174/ajnr.a2621
  110. Current Opinion in Pulmonary Medicine, 11, 373 (2005)
  111. Kaatz S., Douketis J. D., Zhou H., Gage B. F., White R. H., Risk of stroke after surgery in patients with and without chronic atrial fibrillation, 10.1111/j.1538-7836.2010.03781.x
  112. TAFUR A. J., McBANE R., WYSOKINSKI W. E., LITIN S., DANIELS P., SLUSSER J., HODGE D., BECKMAN M. G., HEIT J. A., Predictors of major bleeding in peri-procedural anticoagulation management : Predictors of peri-procedural bleeding, 10.1111/j.1538-7836.2011.04572.x
  113. Turpie A. G. G., Kreutz R., Llau J., Norrving B., Haas S., Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor : , 10.1160/th12-03-0209
  114. Huisman M. V., Lip G. Y. H., Diener H.-C., Brueckmann M., van Ryn J., Clemens A., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice : , 10.1160/th11-10-0718
  115. Nutescu Edith A, Spinier Sarah A, Wittkowsky Ann, Dager William E, Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings, 10.1345/aph.1l194
  116. Lakkireddy Dhanunjaya, Reddy Yeruva Madhu, Di Biase Luigi, Vallakati Ajay, Mansour Moussa C., Santangeli Pasquale, Gangireddy Sandeep, Swarup Vijay, Chalhoub Fadi, Atkins Donita, Bommana Sudharani, Verma Atul, Sanchez Javier E., Burkhardt J. David, Barrett Conor D., Baheiry Salwa, Ruskin Jeremy, Reddy Vivek, Natale Andrea, Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation, 10.1016/j.jacc.2013.11.039